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Congenital Chagas disease, a neglected tropical disease, endemic in Latin America, is associated with premature labor and
miscarriage. During vertical transmission the parasite Trypanosoma cruzi (T. cruzi) crosses the placental barrier. However, the
exact mechanism of the placental infection remains unclear. We review the congenital transmission of T. cruzi,p a r t i c u l a r l yt h e
role of possible local placental factors that contribute to the vertical transmission of the parasite. Additionally, we analyze the
diﬀerent methods available for studying the congenital transmission of the parasite. In that context, the ex vivo infection with T.
cruzi trypomastigotes of human placental chorionic villi constitutes an excellent tool for studying parasite infection strategies as
well as possible local antiparasitic mechanisms.
1.Introduction
Chagas disease was ﬁrst described by the Brazilian physician,
Carlos Chagas, in 1909. He identiﬁed the causal agent,
the protozoan Trypanosoma cruzi (T. cruzi), the vectorial
transmission and insect reservoirs as well as the clinical signs
and symptoms. In other words, he described the complete
cycleofthediseaseandsuggestedthepossibilityofcongenital
transmission [1].
In the human villous hemochorial placenta, fetal and
maternal tissues are separated by a fetal epithelium (the
trophoblast). Within the villous placenta, a single multin-
ucleated cell layer (syncytiotrophoblast) contacts maternal
blood within the intervillous space. Beneath the syncytiotro-
phoblast reside replicating progenitors (cytotrophoblast)
that are separated by a basal lamina from the connec-
tive tissue of villous stroma containing vascular endothe-
lium, ﬁbroblasts, and macrophages. The syncytiotrophoblast
forms a surface of about 12m2 that contacts maternal
blood. Therefore, in case of women with Chagas disease, the
parasite has the opportunity to interact with a large cellular
surface.
The mechanism of T. cruzi congenital transmission can
be studied in diﬀerent ways. One of the possible ways is
through the dual placental perfusion system. The dual per-
fusion that simulates the maternal and fetal circulation could
be an excellent method to study the mechanism of the trans-
mission of the parasite [2]. However, this method requires
complex equipment and very experienced users. Another
possibility is the ex vivo infection of human chorionic villi
explants,inwhichsamplesofplacentaltissue(chorionicvilli)
can be challenged in vitro with T. cruzi or other pathogens.
This system is preferred to analyze the process of infection of
the placental barrier, although the immune system does not
participate. The analysis of infection in animal models is not
treated in this paper because their placentas are not similar
to human placenta. Also, pathological ﬁndings of placentas
are not deeply described because they represent the ﬁnal2 Journal of Tropical Medicine
stage of the placental infection process, and so, it is hard to
understand an ongoing process.
The aim of the present paper is to review the congenital
transmission of T. cruzi, particularly the role of possible
local placental factors which contribute to the vertical
transmission of the parasite and can be studied in the ex vivo
infection model of human chorionic villi explants.
2.ChagasDisease
Chagas disease develops in three phases. The acute phase is
ﬁrst developed, immediately after infection, with high levels
ofparasitemiaandsymptomsinonlysomepatients(regional
lymph node enlargement, bipalpebral unilateral edema, or
Roma˜ na’s sign, and characteristic electrocardiogram alter-
ations). In most cases, acute infection is not accompanied
by clinical ﬁndings, thus moving onto the latent phase that
can last for months or years. The chronic phase, present in
30% of infected individuals, is associated with mega colon,
mega esophagus, degeneration of the autonomous nervous
system, arrhythmias, and abnormal growth of the heart
with progressive insuﬃciency, with evident negative impact
on the patient’s health. In this phase the disease can be
handicapping, and can either be the concurrent or the direct
cause of death. The course of the disease depends on diverse
factors: parasite load at the site of inoculation, both the
parasite’s genetic group and strain, whether it is an infection
denovoorreinfection,thehost’simmunologicstatus,andthe
type of vector (triatomid) [3, 4].
3. Congenital ChagasDisease
Congenital T. cruzi infection is associated with premature
labor, low birth weight, and stillbirths [5–7]. Serologic
prevalence among pregnant women may reach 80%, and
rates of congenital infection vary from 1–21% [8–11]. In
Argentina the transmission rate is estimated between 2–12%
[12]. In Chile, in two of the endemic regions (IV and V
regions), the congenital transmission rate of the parasite
is 8.4% [13]. According to WHO/PAHO the number of
infected women at fertile age is approximately 1.8 million
and it is estimated that 14,400 neonates are being infected
each year [14], this is another reason why this form of
transmission becomes epidemiologically more important.
Additionally, congenital transmission is partly responsible
for the “globalization of Chagas’s disease” [10, 15].
Congenital Chagas transmission implies a T. cruzi
seropositive mother and a postpartum detection of parasites
in the newborn. Congenital Chagas disease is diagnosed by
direct microscopic examination of blood samples, PCR, or
standard serological assays. The latter can be carried out in
infants when IgG antibodies transferred from the mother
have been eliminated (8-9 months after birth).
During congenital transmission, the parasite reaches the
fetus by crossing the placental barrier [16–22]. The fact
that only a percentage of the infected mothers transmit
parasites to their fetuses raises the question of the ability of
the placenta as well as the immunological status of mother
and fetus/newborn to impair the parasite transmission.
Therefore, it is thought that congenital Chagas disease is
the product of a complex interaction between the parasite,
the maternal and fetus/newborn immune responses, and
placental factors [9, 18].
4.The Parasite
T. cruzi is a haemoﬂagellated protozoan of the Kinetoplastida
order and Trypanosomatidae family [22]. The parasite’s
biological cycle includes three cellular forms characterized
by the relative positions of the ﬂagellum, kinetoplast, and
nucleus [23]: (1) trypomastigotes: approximately 20µm
in length and sub terminal kinetoplast. They constitute
the nonreplicative, mammalian infecting cellular form that
is found in the blood and in the posterior intestine of
triatomids. In mammals, this is the cellular form that
disseminates infection through blood. (2) Epimastigotes:
also 20µm in length with a kinetoplast anterior to the
nucleus. They represent the multiplying parasite form in the
triatomid intestine. (3) Amastigotes: approximately 2µmi n
diameter, rounded, with no emergent ﬂagellum. It multiplies
within the mammalian host cells, forming nests, until they
rupture after several cell divisions. Before their release from
the host cells, amastigotes diﬀerentiate into trypomastigotes
which once released, invade the blood stream; they may
then enter any other nucleated cell. Epimastigotes can be
grown in axenic cultures while amastigotes are grown in
cultured mammalian cells, releasing trypomastigotes that
can be harvested to perform in vitro assays.
T. cruzi displays great biological, biochemical, and
genetic diversity; therefore diﬀerent strains of the parasite
have been identiﬁed and classiﬁed into six discrete typing
units (DTUs) [24, 25]. Strains of T. cruzi have been involved
in diﬀerent clinical forms of Chagas disease [26, 27],
thus implicating a diﬀerent genetic population in tissue
tropism, replication, and virulence, and in consequence in
disease outcome. T. cruzi strains corresponding to diﬀerent
DTUs might have relevant consequences on congenital
transmission and fetal/neonatal pathology, even though
Virreira et al. [28]a n dB u r g o se ta l .[ 9] concluded that
congenital transmission of T. cruzi is not associated with
genetic polymorphism of T. cruzi.H o w e v e r ,S o l a n ae ta l .
[29] and Triquell et al. [21] described biological diﬀerences
among subpopulations of T. cruzi in experimental vertical
transmission and placental infection.
5. Mother and Fetus/Newborn
Immune Response
The immune system is fundamental to protect the mother
against the environment, and to prevent damage to the fetus.
During pregnancy the maternal immune system is charac-
terized by a reinforced network of cellular and molecular
recognition, communication, traﬃcking and repair; it raises
the alarm to maintain the wellbeing of the mother and the
fetus. On the other hand, the fetus provides a developing
active immune system that will modify the way the mother
responds to the environment, providing a uniqueness of
the immune system responses during pregnancy [30].Journal of Tropical Medicine 3
A crucial factor to stop, limit, or permit the development
of fetal/neonatal infection relates to the capacity of the
mother and fetus/newborn to mount innate and/or speciﬁc
immune response(s) against pathogens. Clinical studies have
shown a strong association between intrauterine infections
and pregnancy disorders such as abortion, preterm labor,
intrauterine growth retardation, and preeclampsia [31]. As
described above, congenital T. cruzi infection is associated
with some of these pathologies [5–7, 15]. Production of
proinﬂammatory cytokines can be observed in uninfected
newborn from infected mothers [15]. Contrarily, the levels
of inﬂammation markers and activation of NK cells are
rather low in congenitally infected newborns [32]. This data
highly suggests a protective role of such innate defenses
in an uninfected newborn from infected mothers. On the
other hand, maternal T. cruzi-speciﬁc IgG antibodies play
protective roles in mothers and in fetuses when antibodies
are transferred through the placenta [33] and also may
contribute to a reduction in parasitaemia [15].
6. Placenta
Theplacentaistheprincipalsitefortheexchangeofnutrients
and gases between the mother and fetus. This organ plays an
important role in hormone, peptide, and steroid synthesis
necessary for a successful pregnancy [34]. The human
placenta is classiﬁed as a hemochorial villous placenta in
which the free chorionic villi, formed by the trophoblast and
the villous stroma, are the functional units. The trophoblast
contacts maternal blood in the intervillous space, and it is
separated by a basal lamina from the villous stroma, which
is connective tissue containing the vascular endothelium,
ﬁbroblasts, and macrophages (Figure 1)[ 35]. Trophoblast,
basal lamina, and villous stroma with the endothelium of
fetal capillaries form the placental barrier that must be
crossed by diﬀerent pathogens, including T. cruzi, to infect
the fetus during vertical transmission [16–22, 36–41].
Placentas from mother with acute Chagas disease (high
parasitaemia) show severe histopathological changes, such as
extensive necrosis, inﬂammatory inﬁltrate, and amastigote
nests [5]. Contrarily, placentas from mother with chronic
Chagas disease do not present necrotic foci and inﬂamma-
tory inﬁltrate. Although parasite antigens can be visualized
in the villous stroma, the typical amastigote nests are not
present [22]. In accordance with these results, in ex vivo
infected placental explants, though parasite antigens and
DNA can be detected [17, 18, 42], amastigote nests are not
observed. Only few individual parasites can be detected. This
evidence suggests that antiparasite mechanisms may exist




We updated the importance of the presence of the causal
agent of Chagas disease in the intervillous space of human
placentas, the viability of the parasite in this environment,
Figure 1: Electron micrograph of a chorionic villous human
placenta. Picture depicts the intervillous space (1) and the placental
barrier formed by the syncytiotrophoblast (2), a discontinuous
cytotrophoblast (3), basal laminae (asterix), conective tissue, and
fetal vessels (4).
and the process of infection of the placental tissue, mainly by
ex vivo and in vitro studies.
(1) Clearance of T. cruzi from the intervillous space is
associated with the risk of congenital transmission.
Thus, a high parasitaemia, as in acute infection,
correlates with a higher transmission rate [15, 18, 43,
44].Thustheamountofparasitescouldbeanimpor-
tant risk factor for mother to fetus transmission of
T. cruzi. There are only few publications analyzing
the survival of T. cruzi in the placental environment.
Triquell et al. [21], employing chorionic villi ex
vivo and in vitro infection model cocultured with
trypomastigotes from two diﬀerent strains of T.
cruzi, observed that one of the strains presents a
better survival rate than the other in the placental
environment. Furthermore, the two strains of T.
cruzi respond diﬀerently when they were treated
with placental media. Therefore, the great biological,
biochemical, andgenetic diversity ofthe parasitemay
determine, at least partially, the capacity of placental
infection. These results open a new concept, that
placenta might exert a clearance of the parasite from
the intervillous space, and that diﬀerent populations
of T. cruzi have diﬀerent survival capacities in that
environment.
(2) Contact time between T. cruzi and the trophoblast
in the intervillous space: the time that the parasite
remains in the intervillous space in contact with
the syncytiotrophoblast is poorly known. Placental
barrier is constituted by the trophoblast tissue, that
comprises a continuous multinucleated, nonreplicat-
ing cell layer, the syncytiotrophoblast, a replicating4 Journal of Tropical Medicine
Cardiac output in woman 4250 mL/min
In pregnancy: 20% increase in circulating blood volume and 40% increase in cardiac output
Cardiac output in pregnant woman 5950 mL/min
10% of cardiac output reaches the uterus and 80% of this volume reaches the placenta
475 mL/min of blood reaches the placenta
       Low parasitemia (0.1–1 parasite/mL): 
    68544–685440              parasites circulate through 
the placenta in 24 hours
    High parasitemia (over 40  parasite/mL): 
    more than 27 million parasites circulate
          through the placenta in 24 hours
Figure 2: Estimation of T. cruzi contact with the placenta in infected mothers.
layer of cytotrophoblasts that fuses with the STB,
a basal lamina, and an underlying villous stroma
or connective tissue, that includes vascular endothe-
lium [35]. The placental barrier must be crossed
by the parasites, therefore the time that T. cruzi
trypomastigotes stay in the intervillous space and
interact with the syncytiotrophoblast is of outmost
importance. Shippey et al. [45]i nad u a lp e r f u s i o n
systemofplacentalcotyledonsobservedT.cruziDNA
in the maternal eﬄuents at 30min, 60min, and
90min after injection an only one bolus of T. cruzi
trypomastigotes through the maternal perfusate.
There was no parasite DNA in the fetal eﬄuent,
indicating there was no passage to fetal circulation
despite the great concentration of parasites injected.
However, the perfusion time was only 120min in
these experiments. Contrarily, in the ex vivo infection
of chorionic villi explants, a reproducible infection
is obtained after 24 hours of coincubation with the
parasite [17]. However, the perfusion experiments
indicate that T. cruzi is present in the intervillous
space at least for an hour and half. Despite this long
time of interaction, T. cruzi was not able to invade or
survive in the placental barrier, indicating a defense
mechanism of the placental barrier against the causal
parasite of Chagas.
(3) Placental infection: the ex vivo and in vitro infection
of human chorionic villi explants from human term
placenta with the parasite is an excellent and easy
way to study the mechanism of cellular and tissue
invasion mechanisms. The explants can be kept in
culture for several days [46], where constituent cells
and tissues are in a more physiological condition
than their isolated counterparts in monolayer cell
culture models. Another advantage of this model is
that the cells retain physical contact with the basal
lamina and continue to receive paracrine growth
factor signals from the underlying villous stroma.
In our laboratories, we have established the optimal
conditions for the ex vivo infection of chorionic
villi explants with T. cruzi [17, 18, 20, 21, 36–41,
47]. The coincubation of 105 or 106 trypomastigotes
produces a reproducible infection of the chorionic
villi [17]. This parasite’s concentration may seem to
be extremely high, but if we consider the amount
of blood that circulates through the placenta every
day, and then calculate the number of parasites
that reaches the placenta, the parasite concentration
recommended for ex vivo infection is not high.
Therefore, if we consider that the cardiac output in
women is 4250mL/min, and that during pregnancy
the circulating blood volume increases in 20% and
thecardiacoutputin40%.Thenthecardiacoutputin
pregnant women is 5950mL/min. From this output,
10% reaches the pregnant uterus and 80% of this
volume reaches the placenta. Taking into account
all the data, a volume of 475mL/minute of blood
reaches the placenta [48]. Considering a parasitemia
as low as 0,1 to 1 parasite/mL, a total of 68544 to
685440 parasites circulate through the placenta in
24 hours (Figure 2). On the other hand, in pregnant
women with acute Chagas disease, Torrico et al.
[11]havereportedparasitemiasover40parasites/mL;
therefore, in this condition a total of 27 million
parasites circulate in 24 hours in the placenta. If we
consider all these data, our experimental conditions
are not far from in vivo conditions.
The trophoblast, the ﬁrst tissue that is in contact with
the parasite in the intervillous space, constitutes a potential
barrier to T. cruzi. We observed that the most notable tissue
damage induced by T. cruzi in the chorionic villi explants
is the trophoblast detachment and destruction. Additionally,
theparasiteinducesselectivedisorganizationofbasallamina,
collagen I destruction [17], and apoptosis (especially in the
trophoblast) in infected chorionic villi explants [49]. In
accordance, we detected similar histopathological changes inJournal of Tropical Medicine 5
placentas from women with chronic Chagas disease ([22]
manuscript in this number of J. of Tropical Medicine).
Therefore, the similar histopathological changes observed
in chagasic mothers and in ex vivo infected chorionic villi,
validates the latter model. The extracellular matrix alteration
produced by T. cruzi not only promotes its motility in tissues
and its entrance into cells, but also alters the presence of
cytokines and chemokines, which in turn permits T. cruzi
to modulate and evade both the inﬂammatory and immune
responses [16, 50, 51]. Alternatively, these changes in ECM
function may be part of a local placental defense mechanism,
which could explain why only very few parasites can be
detected in the placenta. Similar eﬀects can be observed in
the chorionic villi explants during ex vivo infection, since
placental explants do not allow a sustained infection by
T. cruzi [19]. Thus, the placenta controls the productive
infection of T. cruzi in chorionic villous and exerts a
protective function to fetus.
In order to understand the mechanism by which T.
cruzi fuses with trophoblast plasma membrane, Calder´ on
and Fabro [52] studied the interaction between syncytial
plasma membranes from the human placenta and from the
parasites, founding modiﬁcations of membrane lipids and
proteins of the syncytiotrophoblast. Additionally, modiﬁca-
tions of enzyme activities in the chorionic villi have been
described [37–39]. For instance, placental alkaline phos-
phatase (PLAP) is a glycosylphosphatidylinositol anchored
plasma membrane protein present in the trophoblast that
decreases its activity in chagasic women and is related to
congenital transmission [53]. In ex vivo infected chorionic
villi, pretreatment of the placental tissue with phospholipase
C prevents the parasite-induced decrease of PLAP activity
and signiﬁcantly reduces the infectivity of T. cruzi. These
results are consistent with a pathogenetic role for placental
alkaline phosphatase in congenital Chagas disease [36, 54].
Additionally, T. cruzi induces in the ex vivo infection model
anincreaseoflysosomalvesiclesinthetrophoblast,whichare
fundamental during cell invasion of the parasite [36–39].
Analyzing the process of trophoblast infection by T.
cruzi in an in vitro system culturing monolayer trophoblasts
cells in interaction with infective trypomastigotes, it was
shown that two types of chorionic villi trophoblasts, syn-
cytiotrophoblast, and cytotrophoblast have a diﬀerential
susceptibility to infection by the causal agent of congenital
Chagas disease [55]. The reduced infection in the syncy-
tiotrophoblast was associated to fewer viable parasites in the
culture medium and increased levels of nitric oxide. These
results emphasize the importance of the integrity of the ﬁrst
placental barrier, the syncytiotrophoblast, in order to avoid
a T. cruzi infection of the inner trophoblasts or stromal
chorionic villi cells. As it was described above, structural
t r o p h o b l a s ta l t e r a t i o ni sac o m m o ns i g no fm i s c a r r i a g e s
and premature births in placentas of chagasic women and
strongly associated to the congenital transmission of T.
cruzi. In these clinical situations, the detachment of the
ﬁrst placental barrier is a common sign which is also
associated to parasitism of the placental tissue [9]. Thus,
diﬀerential infection between the ﬁrst placental barrier with
respect to the inner trophoblast or stromal cells could
represent a mechanism of invasion of the human placenta by
T. cruzi.
8. Conclusion
Congenital Chagas transmission constitutes an increasing
public health problem, and it is responsible for the urban-
ization and spreading of the disease to nonendemic areas of
Latin America, United States of America, and Europe [18,
21]. The fact that the ex vivo infection of the chorionic villi
explants with the parasite reproduces the in vivo infection
in terms of cellular changes and infectivity makes it an
excellent tool for studying parasite infection strategies as well
as possible local antiparasitic mechanisms.
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